Advertisement
BMRN vs REGN
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMRN is a Hold and REGN is a Hold.
BMRN in downward trend: 10-day moving average crossed below 50-day moving average on September 25, 2026
The 10-day moving average for BMRN crossed bearishly below the 50-day moving average on September 25, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 72%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BMRN as a result. In 55 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 65%.
BMRN moved below its 50-day moving average on September 22, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMRN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
The Aroon Indicator for BMRN entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BMRN's RSI Indicator exited the oversold zone, 23 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMRN advanced for three days, in 166 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
BMRN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. BMRN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.674) is normal, around the industry mean (2.978). BMRN's P/E Ratio (147.757) is considerably higher than the industry average of (-0.692). Projected Growth (PEG Ratio) (0.348) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (134.267) among similar stocks. P/S Ratio (3.727) is also within normal values, averaging (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
REGN's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for REGN turned positive on October 14, 2026. Looking at past instances where REGN's MACD turned positive, the stock continued to rise in 33 of 49 cases over the following month. The odds of a continued upward trend are 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where REGN's RSI Indicator exited the oversold zone, 18 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on REGN as a result. In 57 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.
Following a +5.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where REGN advanced for three days, in 207 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
REGN moved below its 50-day moving average on October 19, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for REGN crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where REGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
REGN broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for REGN entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. REGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 86 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.539) is normal, around the industry mean (2.978). P/E Ratio (18.678) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (1.238) is also within normal values, averaging (9.059). Dividend Yield (0.005) settles around the average of (134.267) among similar stocks. P/S Ratio (5.339) is also within normal values, averaging (438.009).
BMRN | REGN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 54 | 11 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 98 Overvalued | 88 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 86 | |
SMR RATING 1..100 | 89 | 59 | |
PRICE GROWTH RATING 1..100 | 50 | 50 | |
P/E GROWTH RATING 1..100 | 1 | 16 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
REGN's Valuation (88) in the Biotechnology industry is in the same range as BMRN (98). This means that REGN’s stock grew similarly to BMRN’s over the last 12 months.
REGN's Profit vs Risk Rating (86) in the Biotechnology industry is in the same range as BMRN (100). This means that REGN’s stock grew similarly to BMRN’s over the last 12 months.
REGN's SMR Rating (59) in the Biotechnology industry is in the same range as BMRN (89). This means that REGN’s stock grew similarly to BMRN’s over the last 12 months.
REGN's Price Growth Rating (50) in the Biotechnology industry is in the same range as BMRN (50). This means that REGN’s stock grew similarly to BMRN’s over the last 12 months.
BMRN's P/E Growth Rating (1) in the Biotechnology industry is in the same range as REGN (16). This means that BMRN’s stock grew similarly to REGN’s over the last 12 months.
| BMRN | REGN | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 77% | 1 day ago 67% |
| Stochastic ODDS (%) | 1 day ago 70% | 1 day ago 61% |
| Momentum ODDS (%) | 5 days ago 65% | 1 day ago 61% |
| MACD ODDS (%) | N/A | 1 day ago 67% |
| TrendWeek ODDS (%) | 1 day ago 64% | 1 day ago 64% |
| TrendMonth ODDS (%) | 1 day ago 63% | 1 day ago 62% |
| Advances ODDS (%) | 5 days ago 59% | 5 days ago 65% |
| Declines ODDS (%) | 1 day ago 61% | 1 day ago 56% |
| BollingerBands ODDS (%) | 1 day ago 70% | 1 day ago 60% |
| Aroon ODDS (%) | 1 day ago 65% | 1 day ago 68% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMRN’s FA Score shows that 1 FA rating(s) are green while REGN’s FA Score has 1 green FA rating(s).
- BMRN’s FA Score: 1 green, 4 red.
- REGN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMRN’s TA Score shows that 4 TA indicator(s) are bullish while REGN’s TA Score has 4 bullish TA indicator(s).
- BMRN’s TA Score: 4 bullish, 5 bearish.
- REGN’s TA Score: 4 bullish, 6 bearish.
Price Growth
BMRN (@Biotechnology) experienced а -1.30% price change this week, while REGN (@Biotechnology) price change was +2.52% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -7.86%. For the same industry, the average monthly price growth was -18.66%, and the average quarterly price growth was -19.56%.
Reported Earning Dates
BMRN is expected to report earnings on Nov 03, 2026.
REGN is expected to report earnings on Oct 30, 2026.
Industries' Descriptions
@Biotechnology (-7.86% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
BMRN and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMRN has been loosely correlated with VRTX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if BMRN jumps, then VRTX could also see price increases.
| Ticker / NAME | Correlation To BMRN | 1D Price Change % | ||
|---|---|---|---|---|
| BMRN | 100% | -0.02% | ||
| VRTX - BMRN | 42% Loosely correlated | +0.44% | ||
| AXON - BMRN | 42% Loosely correlated | -1.84% | ||
| IBO - BMRN | 42% Loosely correlated | +14.18% | ||
| VRDN - BMRN | 40% Loosely correlated | +9.30% | ||
| MIRM - BMRN | 37% Loosely correlated | +2.62% | ||
More | ||||
REGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, REGN has been loosely correlated with VRTX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then VRTX could also see price increases.
| Ticker / NAME | Correlation To REGN | 1D Price Change % | ||
|---|---|---|---|---|
| REGN | 100% | -1.10% | ||
| VRTX - REGN | 43% Loosely correlated | +0.44% | ||
| RPRX - REGN | 36% Loosely correlated | -1.13% | ||
| BMRN - REGN | 36% Loosely correlated | -0.02% | ||
| ARQT - REGN | 36% Loosely correlated | +10.65% | ||
| INCY - REGN | 33% Loosely correlated | +0.16% | ||
More | ||||